Tech Company Financing Transactions
X4 Pharmaceuticals Funding Round
X4 Pharmaceuticals closed a $37.5 million Series A financing round on 12/14/2015. Backers included Cormorant Asset Management and Sanofi-Genzyme BioVentures.
Transaction Overview
Company Name
Announced On
12/14/2015
Transaction Type
Venture Equity
Amount
$37,500,000
Round
Series A
Investors
Cormorant Asset Management (Lead Investor)
Proceeds Purpose
X4 will launch multiple clinical studies with X4P-001 in 2016 in advanced cancers, including refractory clear cell renal cell carcinoma (ccRCC) and a second solid tumor indication. A second drug program, X4P-002, which is currently in pre-clinical development, is being optimized for the treatment of brain cancers, and is expected to enter the clinic in 2017.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
955 Massachusetts Ave. 4th Floor 140
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and increase the ability for T-Cells to track and destroy cancer cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paula Ragan
Chief Financial Officer
Adam Mostafa
Chief Medical Officer
Kenneth Gorelick
VP - Human Resources
Ronny Mosston
VP - Operations
Mary DiBiase
VP - Operations
Celeste DiJohnson
VP - Regulatory Affairs
Tarek Ebrahim
Browse more venture capital transactions:
Prev: 12/14/2015: Lens Vector venture capital transaction
Next: 12/14/2015: MIOX venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs